Author

Jordi Guardiola Capon 1

1 Hospital Universitari de Bellvitge,Gastroenterology,HOSPITALET DE LLOBREGAT,Spain

CLINICAL DIFFERENTIAL CHARACTERISTICS OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD) OF ONSET IN PEDIATRIC AGE COMPARED TO PATIENTS DIAGNOSED IN ADULTHOOD

Maria Chaparro Sanchez, Ana Garre, Elena Ricart, Valle García-Sánchez, Carlos Taxonera, Miriam Mañosa, Isabel Vera Mendoza, Miguel Mínguez, Federico Argüelles, Luisa de Castro, M Arroyo, Antonio López-Sanromán, Montserrat Rivero Tirado, Jordi Guardiola Capon, María Dolores Martín-Arranz, Belen Beltran, Jesús Barrio, Sabino

CAN A PATIENT RATE THE ACTIVITY OF THEIR CROHN´S DISEASE THROUGH A MOBILE APP? THE MEDICROHN STUDY. 

Ana Echarri Piudo, Isabel Vera Mendoza, Jordi Guardiola Capon, Virginia Ollero, Beatriz Castro, Francisco Gallego, Mariam Aguas, Maria Chaparro Sanchez, D Ceballos, Claudia Arajol, Pilar Robledo Andrés, Sabino Riestra, Ignacio Marín-Jiménez, Pilar Nos Mateu, S García-López

MANAGEMENT AND OUTCOME OF SEVERE ATTACKS OF ULCERATIVE COLITIS IN THE ERA OF BIOLOGICALS

Jordina Llaó, Juan Enrique Naves, Alexandra Ruiz Cerulla, Jordi Gordillo, Miriam Mañosa Ciria, EDUARD CABRE, Esther García-Planella, Jordi Guardiola Capon, Eugeni Domenech Morral, Jordi Guardiola Capon

PROGNOSTIC VALUE OF COMPLETE REMISSION IN PATIENTS WITH MUCOSAL HEALING IN ULCERATIVE COLITIS

Triana Lobaton Ortega, Talat Bessissow, Gert De Hertogh, Alexandra Ruiz Cerulla, Severine Vermeire, Gert Van Assche, Raf Bisschops, Jordi Guardiola Capon, Marc Ferrante

PROGNOSTIC VALUE OF THE MAGNITUDE OF CYTOMEGALOVIRUS REACTIVATION EVALUATED BY IMMUNOHISTOCHEMICAL STAINING IN PATIENTS WITH ULCERATIVE COLITIS.

Ariadna Clos Parals, Paula Rodríguez-Martínez, Miriam Mañosa Ciria, A. Ruiz-Cerulla, Mª José Paúles, Jprdina Llao, Jordi Gordillo, Caterina Fumagalli, Triana Lobaton Ortega, Isabel Ojanguren, EDUARD CABRE, Jordi Guardiola Capon, Eugeni Domenech Morral

INTESTINAL MICROBIOTA BIOMARKERS AS A NEW TOOL TO SUPPORT IRRITABLE BOWEL SYNDROME DIAGNOSTICS

Joan Amoedo, Leyanira Torrealba, Sara Ramió-Pujol, Lia Oliver, Anna Bahí, Marta Serrano, Marta Malagón, D Busquets, Pau Gilabert, Jordi Guardiola Capon, Mariona Serra-Pagès, L Jesús Garcia-Gil, Xavier Aldeguer

INFLIXIMAB POPULATION PHARMACOKINETIC MODELLING IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: ESTIMATION OF INDIVIDUAL PHARMACOKINETIC PARAMETERS AND TROUGH LEVELS PREDICTION

Lorena Rodríguez-Alonso, Eugenia Santacana, Núria Padullés, Helena Colom, Ariadna Padullés, Claudia Arajol, Sara Cobo, Alexandra Ruiz, Francisco Rodriguez, Jordi Bas, Joan Climent, Francisco Morandeira, Jordi Guardiola Capon

APPRECIA: ADALIMUMAB VS AZATHIOPRINE IN THE PREVENTION OF CROHN’S DISEASE RECURRENCE AFTER SURGICAL RESECTION. A GETECCU MULTICENTER RANDOMIZED TRIAL.

Antonio López San Román, Isabel Vera Mendoza, Eugeni Domenech Morral, Carlos Taxonera, Vicente Vega, Ignacio Marín-Jiménez, Jordi Guardiola Capon, Luisa Castro, Maria Esteve Comas, Valle García, Daniel Ceballos, Pilar Martínez-Montiel, Javier Gisbert, Miguel Mínguez, Ana Echarri Piudo, Xavier Calvet Calvo, Jesús Barrio, Jo

EVOLUTION AFTER ANTI-TNF DRUG DISCONTINUATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD): A MULTICENTER LONG-TERM FOLLOW-UP STUDY

María José Casanova González, Maria Chaparro Sanchez, V. García-Sánchez, O Nantes, E. Leo, Maria Rojas-Feria, Aranzazu Jauregui Amezaga, S García-López, J. M. Huguet, Joan Tosca, M P Martinez-Montiel, Federico Argüelles, M Aicart, I Marín, M Gómez-García, F Muñoz, M Esteve, L Bujanda, X Cortés, Juan Ramón Pineda, E Domè

EXTRACOLONIC NEOPLASIAS IN INFLAMMATORY BOWEL DISEASE PATIENTS: DATA FROM THE GETECCU ENEIDA REGISTRY

Maria Chaparro Sanchez, Jose Manuel Benitez, Alicia López-García, A. Juan, Jordi Guardiola Capon, Miguel Mínguez, Xavier Calvet Calvo, L Márquez, L Fernández-Salazar, L Bujanda, Antonio López San Román, Y Zabana, Rufo H. Lorente, J Barrio, E Hinojosa, Marisa Iborra, M Domínguez-Cajal, M. Van Domselaar, M F García-Sepulcre

Item 1 - 10 / 20
1
2
We use cookies in order to provide you with a better browsing experience. This includes third-party cookies for traffic analyzation purposes. See here for more information.
OK